| Muscular Atrophy |
1 |
1 |
| Myasthenia Gravis |
0 |
0.94 |
| Washington |
0 |
0.47 |
| Biologic Therapy |
0 |
0.43 |
| Fatigue |
0 |
0.42 |
| Adverse Effects |
0 |
0.38 |
| Washington DC |
0 |
0.36 |
| CAR-T |
0 |
0.31 |
| Muscle |
0 |
0.28 |
| Antineoplastic Drug |
0 |
0.23 |
| Monoclonal Antibody |
0 |
0.23 |
| Receptors |
0 |
0.23 |
| Skeletal Myoblasts |
0 |
0.22 |
| Patient Safety |
0 |
0.21 |
| Immunocompromise |
0 |
0.19 |
| North Carolina |
0 |
0.19 |
| Translational Research |
0 |
0.19 |
| Biomarker |
0 |
0.14 |
| Clinical Research |
0 |
0.14 |
| Insurance |
0 |
0.14 |
| MicroRNA |
0 |
0.14 |
| Healthcare and Medical Technology |
0 |
0.1 |
| Antigens |
0 |
0.09 |
| Drug Costs |
0 |
0.09 |
| Health Care Economics |
0 |
0.09 |
| Intravenous |
0 |
0.09 |
| Targeted Cancer Therapy |
0 |
0.09 |
| Tolerance |
0 |
0.09 |
| Weakness |
0 |
0.09 |
| Genomic Medicine |
0 |
0.08 |
| Lipids Management |
0 |
0.08 |
| Revenue and Practice Management |
0 |
0.08 |
| Cardiovascular Risk Management |
0 |
0.06 |